Physician profile
Robert L Glover
NPI 1164712378
$87,534.59
in general payments reported to CMS, 2019-2025
22 companies · $31K in 2025
The $31K reported for 2025 was more than what 96% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,624 · 2020: $4,729 · 2021: $4,682 · 2022: $11K · 2023: $15K · 2024: $17K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $4,924 · Travel and Lodging: $4,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,188.00 |
| Food and Beverage | $4,924.45 |
| Travel and Lodging | $4,219.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $47,124.40 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurelis, INC. | $26,780.89 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $10,995.63 | 2023-2025 | |
| Sk Life Science, INC. | $683.86 | 2020-2024 | Xcopri |
| Neuropace, INC. | $658.29 | 2019-2024 | |
| Ucb, INC. | $393.12 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Merck Sharp & Dohme LLC | $169.23 | 2023 | Verquvo |
| Boston Scientific Corporation | $164.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $96.91 | 2021 | |
| Pfizer INC. | $82.66 | 2025 | |
| Abbvie INC. | $77.04 | 2021-2025 | |
| Amgen INC. | $74.53 | 2022 | |
| Irhythm Technologies, INC. | $33.91 | 2023 | Zio Xt Patch |
| Zogenix INC. | $31.02 | 2021 | |
| Abbott Laboratories | $28.57 | 2025 | Jot Dx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $24.28 | 2024 | Daxxify |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.43 | 2022 | |
| Greenwich Biosciences, INC. | $22.02 | 2020 | |
| Biogen, INC. | $21.35 | 2021 | |
| Globus Medical, INC. | $18.33 | 2025 | Senza |
| Aquestive Therapeutics, INC. | $15.75 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.